Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

14.50
+1.6212.58%
Post-market: 14.870.3700+2.55%19:59 EDT
Volume:12.43M
Turnover:174.91M
Market Cap:1.43B
PE:-2.49
High:14.58
Open:13.22
Low:13.20
Close:12.88
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:2.64
T/O Rate:15.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-4.90
PE(LYR):-2.49

Loading ...

Ultragenyx Pharmaceutical Inc: Reaffirms 2026 Financial Guidance

THOMSON REUTERS
·
May 06

Ultragenyx Pharmaceutical Inc: Remain on Path to Profitability in 2027

THOMSON REUTERS
·
May 06

Ultragenyx CFO Howard Horn disposes 4,683 shares worth $116,607.70

Reuters
·
May 05

Press Release: WisdomTree Announces First Quarter 2026 Results

Dow Jones
·
May 01

Northwest Bio appoints Annalisa Jenkins as strategic adviser

Reuters
·
May 01

Ultragenyx Pharma Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 29

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

GlobeNewswire
·
Apr 29

Ultragenyx price target lowered to $43 from $44 at Barclays

TIPRANKS
·
Apr 29

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 29

Ultragenyx grants 36,447 inducement RSUs to 12 new hires

Reuters
·
Apr 25

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 25

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Medpace Holdings (MEDP) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 24

Wedbush Lifts Price Target on Ultragenyx Pharmaceutical to $27 From $25, Keeps Neutral Rating

MT Newswires Live
·
Apr 21

Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 17

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

TIPRANKS
·
Apr 16

BROAD ARROW AUCTIONS TO OFFER EXTREMELY RARE GORDON MURRAY AUTOMOTIVE T.50 VIA LIVE AUCTION DURING THE CALIFORNIA MILLE

GlobeNewswire
·
Apr 11

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 09

Ultragenyx says FDA accepts UX111 gene therapy BLA resubmission, sets Sept. 19 PDUFA date

Reuters
·
Apr 02

Ultragenyx Pharmaceutical Inc - FDA Sets Pdufa Action Date for Ux111 on September 19, 2026

THOMSON REUTERS
·
Apr 02

Ultragenyx Announces U.S. FDA Acceptance of Bla Resubmission for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
Apr 02